Mimedx (MDXG) Net Income towards Common Stockholders (2011 - 2026)

Mimedx has disclosed Net Income towards Common Stockholders across 15 years of filings, most recently posting -$10.9 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$10.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.9 million (down 132.97% YoY), and the FY2025 annual result was $48.6 million, up 15.67% from the prior year.
• Net Income towards Common Stockholders came in at -$10.9 million for Q1 2026 at Mimedx, down from $7.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $44.8 million in Q4 2023 to a low of -$12.5 million in Q2 2022.
• The 4-year median for Net Income towards Common Stockholders is $7.4 million (2024), against an average of $4.6 million.
• Peak annual rise in Net Income towards Common Stockholders reached 681.83% in 2022, while the deepest fall reached 281.44% in 2022.
• Mimedx's Net Income towards Common Stockholders stood at $8.1 million in 2022, then surged by 451.13% to $44.8 million in 2023, then tumbled by 83.41% to $7.4 million in 2024, then tumbled by 246.01% to -$10.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$10.9 million (Q1 2026), $7.4 million (Q4 2024), and $7.9 million (Q3 2024), per Business Quant data.